Micafungin activity against Candida albicans with diverse azole resistance phenotypes

被引:19
作者
Richards, Theresa S. [1 ,2 ]
Oliver, Brian G. [2 ]
White, Theodore C. [1 ,2 ]
机构
[1] Univ Washington, Sch Publ Hlth & Community Med, Dept Global Hlth, Seattle, WA 98195 USA
[2] Seattle Biomed Res Inst, Seattle, WA 98109 USA
关键词
echinocandins; antifungals; XTT;
D O I
10.1093/jac/dkn156
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The purpose of this study was to investigate whether mechanisms of azole resistance in Candida albicans contribute to reduced micafungin activity in vitro. Methods: MICs were determined for a collection of strains with well-characterized mechanisms of azole resistance obtained from systemic, oral and vaginal infections. This collection of strains includes those with resistance-associated phenotypes. All known molecular mechanisms of azole resistance are included in this set of isolates (alone or in combination). Micafungin activity was further investigated for a subset of isolates by agar dilution. Results: There was no correlation between any of the azole resistance mechanisms or resistance phenotypes and micafungin activity as determined by MIC, even in isolates with cross-resistance to multiple azole drugs. Overexpression of the ABC transporter CDR2 has been suggested to contribute to reduced echinocandin activity in agar dilution studies. By broth microdilution, there was no difference in MIC between the pump overexpressors and the collection as a whole. However, azole-resistant isolates from matched strains exhibited a small increase in their micafungin MICs relative to their susceptible controls. By agar dilution analysis, multiple CDR2-overexpressing strains exhibited reduced growth in the presence of micafungin relative to the laboratory strain SC5314. Conclusions: Azole resistance mechanisms do not contribute to increased micafungin MIC as determined by broth microdilution. However, within sets of matched isolates, strains overexpressing CDR2 had a slight increase in micafungin MIC. Changes in micafungin susceptibility are associated with CDR2 overexpression in agar dilution tests.
引用
收藏
页码:349 / 355
页数:7
相关论文
共 39 条
[1]   Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1 [J].
Balashov, Sergey V. ;
Park, Steven ;
Perlin, David S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2058-2063
[2]   Paradoxical effect of echinocandins across Candida species in vitro:: Evidence for echinocandin-specific and Candida species-related differences [J].
Chamilos, Georgios ;
Lewis, Russell E. ;
Albert, Nathaniel ;
Kontoyiannis, Dimitrios P. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) :2257-2259
[3]   Evolution of drug resistance in Candida albicans [J].
Cowen, LE ;
Anderson, JB ;
Kohn, LM .
ANNUAL REVIEW OF MICROBIOLOGY, 2002, 56 :139-165
[4]   A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients [J].
de Wet, N ;
Llanos-Cuentas, A ;
Suleiman, J ;
Baraldi, E ;
Krantz, EF ;
Della Negra, M ;
Diekmann-Berndt, H .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (06) :842-849
[5]   A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis [J].
de Wet, NTE ;
Bester, AJ ;
Viljoen, JJ ;
Filho, F ;
Suleiman, JM ;
Ticona, E ;
Llanos, EA ;
Fisco, C ;
Lau, W ;
Buell, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (07) :899-907
[6]   Echinocandin antifungal drugs [J].
Denning, DW .
LANCET, 2003, 362 (9390) :1142-1151
[7]   Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors [J].
Douglas, CM ;
DIppolito, JA ;
Shei, GJ ;
Meinz, M ;
Onishi, J ;
Marrinan, JA ;
Li, W ;
Abruzzo, GK ;
Flattery, A ;
Bartizal, K ;
Mitchell, A ;
Kurtz, MB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2471-2479
[8]   In vitro activity of micafungin (FK-463) against Candida spp.:: Microdilution, time-kill, and postantifungal-effect studies [J].
Ernst, EJ ;
Roling, EE ;
Petzold, CR ;
Keele, DJ ;
Klepser, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) :3846-3853
[9]  
Espinel-Ingroff Ana, 2003, Revista Iberoamericana de Micologia, V20, P121
[10]   In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole [J].
Fung-Tomc, JC ;
White, TC ;
Minassian, B ;
Huczko, E ;
Bonner, DP .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 35 (02) :163-167